Disease Description
Crohn’s disease is an inflammatory bowel disease (IBD). Although Crohn’s is typically found in the last part of the small intestine and the first part of the large intestine, it can be found anywhere in the digestive tract, including the mouth and anus.
The main symptoms of Crohn’s are:
-Belly pain
-Diarrhea (sometimes with blood; some have it 10-20 times per day)
-Unexplained weight loss
-Mouth sores
-Bowel Blockages
-Anal tears
-Fistulas (opening between organs) Patients with Crohn’s may go long periods of time with no symptoms or have only a few, but some have the symptoms all the time.
Crohn's disease is an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation; it is classified as a type of inflammatory bowel disease. There has been evidence of a genetic link to Crohn's disease, putting individuals with siblings afflicted with the disease at higher risk. It is understood to have a large environmental component as evidenced by the higher number of cases in western industrialized nations. Males and females are equally affected.[1]
Prevalence
Smokers are three times more likely to develop Crohn's disease. Crohn's disease affects between 400,000 and 600,000 people in North America. Prevalence estimates for Northern Europe have ranged from 27–48 per 100,000. Crohn's disease tends to present initially in the teens and twenties, with another peak incidence in the fifties to seventies, although the disease can occur at any age.[1]
Current Treatments
There are prescription medications that can be taken to manage the symptoms, but there is no cure. At the present time, there are five basic categories of medications used in the treatment of IBD. They are:
-Aminosalicylates
-Corticosteroids
-Immunomodulators
-Antibiotics
-Biologic therapies
Medical treatment for Crohn's disease and ulcerative colitis has two main goals: achieving remission (the absence of symptoms) and, once that is accomplished, maintaining remission (prevention of flare-ups). To accomplish these goals, treatment is aimed at controlling the ongoing inflammation in the intestine—the cause of IBD symptoms.[1]
Evidence for and Proposed Mechanism for Cannabinoid Therapeutics
In a prospective clinical trial by FM Konikoff et al. it was concluded that "a short course (8 weeks) of THC-rich cannabis produced significant clinical, steroid-free benefits to 10 of 11 patients with active Crohn's disease, compared with placebo, without side effects."[2]
1. WebMD online resources
2. Konikoff FM et al. Cannabis Induces a Clinical Response in Patients With Crohn's Disease: A Prospective Placebo-Controlled Study. Clinical Gastroenterology and Hepatology. Volume 11, Issue 10, October 2013, Pages 1276–1280.e1
June 1, 2025, Pre-Launch Success! Click the below Image link to setup your Account and begin your Crypto Journey with us. All Crypto Coin Buyers receive a Limited Time Pre-Launch offer! The Time is Now.
1-Million Strong Killing Cancers!
Click the Below Image to Review our Cancer Drug Comparables
*** Warning this document contains graphic images.
CSi-VIP Awards & NASDAQ Updates
Please Click the Below Image:
The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
Cannabis Science Shareholder FINAL Audit Confirmations
Click the above Image link to view the latest Report
September 23, 2025
Cannabis Science Shareholder Audit Confirmations Underway now!
Click the above Image link to view the latest Report
July 7, 2025
Click the above Image link to view the latest cancer Killing promotional video. This is where you can join our 1-Million Strong youtube page to view more videos as we proceed forward.
June 1, 2025, Pre-Launch Success
Click the above Image link to setup your Account and begin your Crypto Journey with us. All Crypto Coin Buyers receive a Limited Time offer!
*** Warning this document contains exciting images.
Pease Click the Calendar image to book your time to speak with Mr. Dabney about "Your Final CSi-VIP Shareholder Legacy".
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 2024, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.
2025 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2025
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,839,095,296
Fully Diluted:
4,510,547,648
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
GA Raymond,
My Q is when do we get our 2x shares and the gift shares as i have been giving u money over a year ago?????
Thanks for following up Guys! Two things to Remember.
*** One, this is our in-house audit confirmation records for our Financials. We will sign-off...Thanks for following up Guys! Two things to Remember.
*** One, this is our in-house audit confirmation records for our Financials. We will sign-off on our in-house records, complete our Financials, and send the Financials to the Auditors.
*** Two, our “CSi-VIP Shareholder Legacy Reports” that we send out to our CSi-VIPs include ALL your holdings in the Company line by line. However, for those not becoming a CSi-VIP this requires much more time to complete.
We are trusting your initial information to be accurate, CBIS GIFT Shares recipients will have their shareholding records matched and sent in for your CBIS-Gift Shares, and then they will be confirmed, and matched through the Audit process as well, so we are good.
When the Auditors begin their Audit of our Financials they will confirm random information from our shareholders, brokers, and the transfer agent. I doubt the Auditors will call or email everyone, due to the large numbers, but they will do their random checks.
So yes, please do email your information to audit@cannabisscience.com so all the records are in one spot for the Financials.
If you do nothing we will just go with the records we have on file. So, for your peace of mind please send another email to confirm, if it bothers you too much, don't do it. We are confirming everything in -house three times or more from each time we asked you to send it in. It seems we get more shareholders showing up each time we ask, which is great.
So Again, no one needs to purchase anything extra "if you do not want" all the Original CBIS Shares as well as ALL the “CSi-VIP Bonus Shares”, “CSi-Award Shares” and “CBIS-GIFT Shares” will be included in the Financials and Registration Statement to become free trading with the new trading symbol.
They are ALL Common Class Shares the same as the Original CBIS Shares so the final list will be derived from all the past shareholder records on file with the brokerage firms, the transfer agent, and Company in-house records combined.
While we are confirming we have allowed shareholders to acquire their CSi-VIP Status, their GIFT-Shares, and CSi-VIP Bonus Shares to increase their shareholder holdings, smart move Guys! and Congrats!
We have been quite busy working in an order of Priority, so we are behind with the CSi-VIP Legacy Shareholder Reports, but they are certainly ALL on the books of the Company and being done in-between phone calls and progress, so ALL our CSi-VIP, CSi-Award, and CBIS GIFT Shares are on Record, so you are good.
Hopefully this helps, I think it will help based on the questions I get in the appointments, this information will most likely be included in the next UPDATE Email we send out as well, so you are reading it beforehand as we try to stay ahead of the curve.
All the Best Guys! and Congrats! Once again to ALL our Shareholders as we navigate through the final steps to get our shares trading again!
May God Bless us all.
Talk soon.
Raymond - IGWT
Show more